E Blockbuster SAR-CoV2 Disrupters Pre-ICU / Admitted ICU Patient Treatments & COVID-19 T-Cell Vaccine Horizon

In recent months, there has been a flurry of activity within the clinical trial sector. When all trial types are considered, there are over 400 studies exploring approaches to diagnosing, treating, or preventing COVID-19. ClinicalTrials.gov has also reported at least 15 trials leveraging stem cells against COVID-19.

(Click on image to enlarge)

Provided by Capricor Therapeutics, Inc. (c) 2020

Why you need to know Dr. Stephen J. Gould  from John Hopkins, moving forward exosome research & technology 

COVID-19 is the largest pandemic in modern history, with more than ten million confirmed cases and a half million deaths in under six months.

While there is not yet an approved treatment for COVID-19, the scientific, medical, and regulatory agencies are making heroic efforts to bring out new medicines. Numerous COVID-19 product categories have emerged, including vaccines, antibodies, antivirals, repurposed drugs, RNA-based drugs, and cell-based therapies, as well as other approaches, such as enzymes, peptides, and glycoproteins.

This report explores each of these product development categories in detail, presenting the products under development and timelines for them to come to market. Special attention is given to the critical role of cell-based therapies in the management of the global pandemic.

Keeping focused on why M&A with PT $24 - $32 Dollars a share upside

(Click on image to enlarge)

(Click on image to enlarge)

COVID-19 Treatments & Technologies

To accelerate the development of therapies against COVID-19, the repurposing of existing drugs is being explored by numerous market competitors. For example, Barcitinib is being explored because of its anti-inflammatory effect and possible ability to reduce viral entry. A specific dose of the anti-HIV combination, Lopinavir-Nitonavir, is now in clinical trials with Arbidol or Ribavirin. Remdesivir, developed by Gilead Sciences (GILD), was earlier tested in patients with Ebola virus and has shown promise in animal models for MERS and SARS. Remdesivir has reached Phase III in the U.S. and China.

View single page >> |

Disclosure: None.

How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.
James Gornick 5 months ago Author's comment

What will bring all back to work! Joe Biden is clueless... Keeping the eyes on the prize! POTUS Capricor, CAPR yesterday, beat on all numbers and has brought a VLP Vaccine into the long-term solutions FDA TRIALS CAP-1002. talkmarkets.com/.../blockbuster-sar-cov2-disrupters-pre-icu--admitted-icu-patient-treatments--covid-19-t-cell-vaccine-horizon PT $14 - $24 3-12 month outlook.

Rick A. Schneider 5 months ago Member's comment

Lots of good info here, thanks.

James Gornick 5 months ago Author's comment

Thanks for the complement!

James Gornick 5 months ago Author's comment

Good connecting article for why the PT had hit the 52 weeks high $12.32 and maybe the reason for the August 6th or 8th earnings report in jacking the share price towards becoming a true M&A candidate or given the blessings of the FDA's approval for CAP-1002 BLA filing for uses.

READ:

endpts.com/microcap-capricor-soars-on-interim-phii-dmd-data-showing-functional-benefit-for-older-patients/

James Gornick 5 months ago Author's comment

Very Important *****FYI for those seeking the best and earliest buy for both MESO with their BLA pending FDA approval on Remestence-L and CAPR CAP-1002 are just a few we are closely watching.

READ:

bioinformant.com/capricor-developing-treatment-dmd/ Inivio INO just got their BLA approval for their HPV suite of critical advancements in helping those stricken with Throat complications of HPV and that in critically advancing their VGX-3100 towards getting FDA final approvals.

Capricor CAPR has a few irons in the fire coming up when they present their upcoming second-quarter earnings and corporation pipeline status.

READ:

talkmarkets.com/.../blockbuster-sar-cov2-disrupters-pre-icu--admitted-icu-patient-treatments--covid-19-t-cell-vaccine-horizon

The first big iron for CAPR comes with a pending BLA for getting or meeting Orphan Drug Approval Status for their CAP-1002 for male boys and younger adult males with Duchenne muscular dystrophy (DMD) in 7 Major Markets.

This Iron is also quite remarkable with the incredible successes from the uses of MSCs and Exosome biotechnology advancements and the repurposing of their most current pipeline candidates awaiting approvals from the FDA for the accepted treatment protocols COVID-19 SARSCoV2; the eventual Orphan Drug Status for both Capricor CAPR CAP-1002 and Mesoblast LTD MESO for their Remestence-L.

Again, both MESO and CAPR for battling and achieving a true Disrupter Status in this war against China's born novel Coronavirus affecting our entire plant, since possibly October of 2019, when China kept this secret biological weapon hidden from the rest of the entire living masses around our world economies.

Keep up with the currently approved study for CAPR below as a link is provided. ClinicalTrials.gov identifier (NCT number): NCT04338347

READ:

https://clinicaltrials.gov/ct2w/NCT04338347

James Gornick 5 months ago Author's comment

Very Important *****FYI for those seeking the best and earliest buy for both MESO with their BLA pending FDA approval on Remestence-L and CAPR CAP-1002 are just a few we are closely watching. READ: bioinformant.com/capricor-developing-treatment-dmd/ Inivio INO just got their BLA approval for their HPV suite of critical advancements in helping those stricken with Throat complications of HPV and that in critically advancing their VGX-3100 towards getting FDA final approvals. Capricor CAPR has a few irons in the fire coming up when they present their upcoming second-quarter earnings and corporation pipeline status. READ: talkmarkets.com/.../blockbuster-sar-cov2-disrupters-pre-icu--admitted-icu-patient-treatments--covid-19-t-cell-vaccine-horizon The first big iron for CAPR comes with a pending BLA for getting or meeting Orphan Drug Approval Status for their CAP-1002 for male boys and younger adult males with Duchenne muscular dystrophy (DMD) in 7 Major Markets. This Iron is also quite remarkable with the incredible successes from the uses of MSCs and Exosome biotechnology advancements and the repurposing of their most current pipeline candidates awaiting approvals from the FDA for the accepted treatment protocols COVID-19 SARSCoV2; the eventual Orphan Drug Status for both Capricor CAPR CAP-1002 and Mesoblast LTD MESO for their Remestence-L. Again, both MESO and CAPR for battling and achieving a true Disrupter Status in this war against China's born novel Coronavirus affecting our entire plant, since possibly October of 2019, when China kept this secret biological weapon hidden from the rest of the entire living masses around our world economies. Keep up with the currently approved study for CAPR below as a link is provided. ClinicalTrials.gov identifier (NCT number): NCT04338347 READ: https://clinicaltrials.gov/ct2/show/NCT04338347

Leslie Miriam 5 months ago Member's comment

Good article, but that headline is a mouthful. I think you would have gotten far more clicks with something more easily digestible/catchy.

James Gornick 5 months ago Author's comment

I agree, the title of the article was a mouthful! I had a hard time shorting it, mostly due to the sure nature of covering a myriad of treatments and vaccines for ongoing war.

I will use my reply this morning, in taking efforts on getting out my frustrations for a NOVEL CORONAVIRUS that has killed hundreds of thousands, and yet has not met it's match to date.

Yes, I said WAR--being waged upon China's Deadly Gift--sent around the world with a Kiss...

China's well documented "Evil Intents" by the very nature of evil, as driven China determination in becoming the one and only superpower over our free democracies we all seemingly hold so dear.

I say this, because, it seems our LEFT-WING MEDIA and the Tech-Valley of Google's, Amazon's, Apple's, Twitter's, and a host of Democratic DNC elected Governor's, Mayor's, and elected officials throughout the many states and cities; seeing out and out rioting, causing untold damages throughout our United States.

Just getting out my frustrations this morning. I just can't believe the lengths the LEFT-WING Media has taken in trying to effect a presidential election in 2020.

We can all agree, when one can stand behind the cause of when an African American, who had been suffocated with a lethally used choke hold--as the one loan officer wouldn't release pressure--as many were yelling at the other two law enforcement officers to stop George's death as he was killed in Minneapolis, Minnesota, George Floyd's death, at the hands then, three identified law enforcement officers, with one actually being the stone blooded killer.

NO ONE can disagree with the outrage in the senseless killing of George Floyd, in wear legal protest is quite a correct response.

We in NO WAY or in ANY SHAPE, CONDONE what has gone on behind those that lead BLM condoning the extremes of lawlessness, an increase in civilian death's along with those wearing the BLUE as the violence seen over these past several months And within their past history's.

NO ONE should stand-by and allow lawlessness and outright Anarchies, as being played out in Portland, Seattle, Chicago, and other televised news coming out from a trusted NEWS SOURCE of FOX News; as I recommend many to turn towards, if they want the truth and not the FAKE NEWS Agendas.

Yes, FAKE NEWS AGENDAS being waged against our own 1st amendment rights, and though, I do find some other news outlets not afraid in getting out the truth behind all these very Evil and Diabolical efforts being played out right before all of our very eyes.

James Gornick 6 months ago Author's comment

The following link should be kept close at hand when dealing with COVID-19 concerns and timely SARS-CoV2 ICU Patient Treatment Protocols: www.ashp.org/.../ASHP-COVID-19-Evidence-Table.ashx Viewing the Thoracic Concerns: www.atsjournals.org/.../rccm.201908-1581ST

James Gornick 6 months ago Author's comment

The coronavirus disease of the 2019 pandemic caused by the SARS-CoV-2 virus continues to inflict significant morbidity and mortality around the globe. A variety of cardiovascular presentations of SARS-CoV-2 infection have been described so far. However, the impact of SARS-CoV-2 on the right ventricle is largely unknown. Due to its pathophysiologic relevance, the right ventricle finds itself in the eye of the storm of coronavirus disease of 2019, placing it at a higher risk of failure. Increased afterload from acute respiratory distress syndrome and pulmonary embolism, negative inotropic effects of cytokines, and direct angiotensin-converting enzyme 2-mediated cardiac injury from SARS-CoV-2 are potential mechanisms of right ventricle dysfunction in coronavirus disease of 2019. Early detection and treatment of right ventricle dysfunction may lead to decreased mortality and improved patient outcomes in coronavirus disease of 2019. MOBIL COVID-19 PROTOCOLS: https://mobile.health.mil/asp/#/covid-19

DRM 5 months ago Member's comment

"Significant" is subjective. Put this into perspective! Only 9/1,000 of 1 percent of the world population "may" have died from C-19. We will never know the true number because we cannot trust the numbers reported by politicians, or bureaucratic scientists and doctors. Death is inevitable and when you consider that, according to the most "trustworthy" government agency, the CDC, 80% of those who "may" have died from C-19 were over 65 years old and the UN, another "trustworthy" entity, which says that those over 80 years old are 5 times more likely to die, it's not as "significant" as you may think. On the other hand, the flu, for which a vaccine exists, kills people of all ages, even health young people. Again, put things into perspective so you can see the bigger picture.

Angry Old Lady 5 months ago Member's comment

Shh, don't tell DRM, he doesn't really believe in the morbidity of COVID-19. But I'm glad you are helping to spread the word.

James Gornick 5 months ago Author's comment

God bless! Thank you : -)

James Gornick 6 months ago Author's comment

GOOD CONNECTIONS FOR STAYING ON-TOP OF THIS WAR ON CHINA'S DEADLY GIFT SENT AROUND THE WORLD AS COVID-19: www.covid19-druginteractions.org/prescribing-resources liverpool-covid19.s3.eu-west-2.amazonaws.com/lnilz6wi5y5qxy4qw9l5zek8tzvc

James Gornick 6 months ago Author's comment

Good Review for Capricor CAP-1002 Study as further will be released within this next reporting qtr. link.springer.com/.../s00395-020-0795-1.pdf This drug has great efficacy for COVID-19 U.S. hot-spots or uptick of cases for a number of patients meeting ICU status of care. This SARS-CoV2 COVID-19 Infectious Diseases Society of America--Adobe.pdf for current standing protocol treatments has a phenomenal pulse of what doctors are facing on the frontlines as of the current date. www.idsociety.org/.../covid-19-guideline-treatment-and-management/ Trying to educate as many as I can so, the more you know, the more you can spread the word for those who are dealing with COVID-19 themselves, or have a family member or close friends diagnosed and admitted into the hospital. with SARS-CoV2 pre-ICU or already admitted into the ICU.